ARS Pharmaceuticals (SPRY) Q1 2026 earnings review
YoY Growth is Strong, but Severe Seasonality and Soaring Costs Raise Questions
ARS Pharmaceuticals continues to build its foundational prescriber base, with neffy U.S. net product revenue up 125% YoY to $17.5M. However, sequential trends are decelerating rapidly following the Q3 back-to-school peak. The starkest reality for investors is the massive gap between sales and operating expenses: ARS spent $72.2M on SG&A this quarter to generate $22.7M in total revenue. While a looming CVS Caremark formulary addition and pediatric label expansion offer robust upside, the company must prove that prescription renewals and new patient capture can eventually outpace its aggressive cash burn.
🐂 Bull Case
A proposal to add neffy to CVS Caremark's commercial formulary without prior authorization is in final approval stages (targeting July 1, 2026). This removes the largest remaining friction point for prescriber adoption.
The FDA removed the age criteria for the 1 mg neffy dose, opening up the full pediatric market (33 lbs+). Approvals in Europe (EUR neffy 1 mg) and Canada provide additional revenue streams via partner ALK.
🐻 Bear Case
neffy U.S. sales peaked at $31.3M in Q3 2025 during the back-to-school rush and have decelerated for two straight quarters to $17.5M, indicating the baseline recurring revenue model remains weak off-season.
The company increased its sales force to 148 representatives. SG&A hit $72.2M—more than triple total revenue. Even with $201M in liquidity, the path to cash-flow breakeven looks steep without a massive step-up in base volume.
⚖️ Verdict: ⚪
Neutral. The commercial execution is technically solid—expanding access and prescribers—but the financial reality is harsh. The business is heavily dependent on Q3 seasonality, and the $72M quarterly SG&A burn rate requires neffy sales to multiply quickly to justify the valuation.
Key Themes
Sequential Deceleration Highlights Severe Seasonality
U.S. neffy revenue is decelerating sequentially. After peaking at $31.3M in 25Q3, it fell to $20.3M in 25Q4 and $17.5M in 26Q1. While management correctly anticipated Q4 drop-offs, the continued contraction into Q1 shows that the product is highly dependent on the late-summer back-to-school purchasing cycle. The upcoming quarters must prove that renewals can smooth out this curve.
CVS Caremark Unrestricted Access Imminent
Management noted they are in the final stages of approval to add neffy to the CVS Caremark commercial formulary without a prior authorization (PA), effective July 1, 2026. This is a massive driver. Historically, PAs have been the largest administrative hurdle, and unlocking CVS will dramatically reduce abandonment rates and physician friction ahead of the critical 2026 back-to-school season.
Cash Burn and SG&A Outpacing Growth
SG&A expenses are stable but structurally elevated, hitting $72.2M this quarter (up from $60.0M in 25Q4). This was driven by expanding the sales force from 106 to 148 representatives and continued DTC marketing. While management states this was funded via reallocation, a $60.6M net loss on $22.7M in total revenue highlights significant operating deficit. The $201M cash pile provides runway, but limits room for error.
Prescriber Base Continues to Scale
Adoption is accelerating steadily. Over 28,000 healthcare providers have now prescribed neffy, up from 22,500 at the end of 2025. Crucially, approximately 50% are repeat prescribers. This validates the success of the direct-to-consumer campaigns and the new automated retail pharmacy program designed to convert denied claims to a $199 cash price, capturing patients who would otherwise abandon the script.
Pediatric Label Expansion
The FDA's removal of the age criteria for the 1 mg neffy dose in March 2026 is a quiet but critical win. Now, any child or adult weighing 33 lbs or more can utilize neffy. Given that pediatric prescriptions make up over half of all epinephrine prescriptions, removing administrative complexity around age gates will directly support volume growth.
Other KPIs
Total revenue grew 184% YoY but declined sequentially from $28.1M in 25Q4. It includes $17.5M from U.S. neffy, $2.5M in ALK collaboration milestones, and $2.7M in supply revenue.
Cash balance declined by approximately $44M from $245M at the end of 25Q4. Management maintains this is sufficient to fund operations through cash-flow break-even, heavily relying on the assumption that revenue will scale dramatically to meet the >$250M annualized SG&A run rate.
A deceleration in profitability metrics. Loss widened from -$33.9M in 25Q1 and -$41.3M in 25Q4, almost entirely driven by the aggressive commercial scale-up and sales rep expansion.
Guidance
Stable. The pending CVS Caremark contract is expected to carry economics within the company's long-term gross-to-net retention target of roughly 50%. Maintaining this margin while removing Prior Authorization hurdles is a positive execution signal.
Accelerating. With Florida added, 9 state Medicaid plans currently cover neffy without PA. Securing a majority by 2027 will unlock a historically hard-to-reach patient demographic for branded allergy products.
Key Questions
SG&A Normalization Timing
With the sales force now expanded to 148 representatives and DTC campaigns running, at what quarter do you expect SG&A to level off in absolute dollars?
Renewal Rate Reality vs. Intent
Last year, surveys showed a 90% intent-to-refill rate for neffy. As we approach the one-year mark for your earliest cohorts, what is the actual commercial renewal rate you are observing in the data?
CVS Caremark Volume Expectations
If the CVS Caremark unrestricted formulary addition goes live on July 1, how quickly do you expect that to translate into script volume given the historical PA abandonment rates in that channel?
Mitigating the Q1/Q2 Trough
We are seeing severe seasonality with Q1 revenues dropping off significantly from Q3/Q4. Beyond back-to-school, what specific strategies are being deployed to smooth out demand and drive baseline winter/spring volume?